Health
US study identifies 275 million brand new genetic variants
The study, which analysed the genetic code of a quarter of a million volunteers in the US, identified more than 275 million brand-new variants that
EU medicines regulator to review Lilly’s Mounjaro multi-dose pen
The European Union’s health regulator this week will review the use of Eli Lilly’s approved diabetes and obesity drug Munjaro in pre-filling a multi-dose injection
Pfizer’s drug for inflammatory bowel disease has received EU approval
A drug to treat patients with an inflammatory bowel disease called ulcerative colitis has been approved by the European Commission. The approval of Velsipity followed
US FDA approves combination chemotherapy Tagrisso
The US Food and Drug Administration has approved a combination of AstraZeneca’s blockbuster drug Tagrisso with chemotherapy to treat a type of lung cancer. The
Denali-Sanofi’s ALS drug misses mid-stage target
Drug developer Denali Therapeutics said its experimental drug for a fatal neurodegenerative disease failed to halt declining motor function in a mid-stage study. Following the
Asbestos crisis worsens in Sydney schools and supermarkets
Seven more public places in Sydney, including a school, a sports centre and a supermarket, are exposed to asbestos as contamination from the toxic material
US FDA approved for Iovance skin cancer cell therapy
Iovance Biotherapeutics the US health regulator has granted accelerated approval for a cell therapy for adult patients with advanced melanoma, the first such treatment approved
US FDA to review Sarepta’s Duchenne gene therapy for traditional approval
Sarepta Therapeutics said the US FDA will review the application for traditional approval of its gene therapy to treat the muscle atrophy disorder by 21
The US FDA has approved AstraZeneca’s Tagrisso and chemotherapy combination
AstraZeneca’s combination of AstraZeneca’s blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer has been approved by the US Food and
GSK has completed the acquisition of Aiolos Bio for $1.4bn
GSK said Thursday it has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company specialising in respiratory and inflammatory diseases. GSK will pay $1